CN104833810A - 一种补体c3检测方法 - Google Patents
一种补体c3检测方法 Download PDFInfo
- Publication number
- CN104833810A CN104833810A CN201510226757.7A CN201510226757A CN104833810A CN 104833810 A CN104833810 A CN 104833810A CN 201510226757 A CN201510226757 A CN 201510226757A CN 104833810 A CN104833810 A CN 104833810A
- Authority
- CN
- China
- Prior art keywords
- complement
- reagent
- latex
- detection method
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010028780 Complement C3 Proteins 0.000 title claims abstract description 27
- 238000001514 detection method Methods 0.000 title claims abstract description 16
- 102000016918 Complement C3 Human genes 0.000 title claims abstract 13
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 45
- 239000004816 latex Substances 0.000 claims abstract description 14
- 229920000126 latex Polymers 0.000 claims abstract description 14
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920001213 Polysorbate 20 Polymers 0.000 claims abstract description 5
- 239000004793 Polystyrene Substances 0.000 claims abstract description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract description 5
- 229920002223 polystyrene Polymers 0.000 claims abstract description 5
- 238000004132 cross linking Methods 0.000 claims abstract description 4
- 239000002245 particle Substances 0.000 claims abstract description 4
- 238000004879 turbidimetry Methods 0.000 claims abstract description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims abstract 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract 3
- 238000010382 chemical cross-linking Methods 0.000 claims abstract 3
- 239000007788 liquid Substances 0.000 claims abstract 2
- 239000011780 sodium chloride Substances 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 14
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 claims description 8
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 claims description 8
- 238000002835 absorbance Methods 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- 238000001311 chemical methods and process Methods 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 229920000151 polyglycol Polymers 0.000 claims description 2
- 239000010695 polyglycol Substances 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims 1
- 239000008118 PEG 6000 Substances 0.000 claims 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims 1
- 239000012482 calibration solution Substances 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 6
- 241000283707 Capra Species 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 abstract 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 abstract 1
- 239000008055 phosphate buffer solution Substances 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 102100022133 Complement C3 Human genes 0.000 description 17
- 238000012360 testing method Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 3
- 238000010219 correlation analysis Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 1
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明提供一种补体C3检测方法,所述检测方法基于胶乳增强免疫比浊法,为液体双试剂,包括试剂R1与R2,所述试剂R1含PH6.0磷酸盐缓冲液,吐温-20(Tween 20),乙二胺四乙酸二钠(EDTA-2Na),氯化钠,聚乙二醇(PEG6000),叠氮钠;试剂R2为含有补体C3胶乳颗粒的溶液,其特点在于应用化学方法交联,通过水溶性碳化二亚胺(EDC)与N-羟基琥珀酰亚胺(NHS)使羊抗人补体C3抗血清与羧化聚苯乙烯胶乳共价交联,形成补体C3胶乳试剂。本试剂灵敏度高,特异性强,试剂配制简单,值得进一步推广使用。
Description
技术领域:
本发明属于生物技术领域,提供一种补体C3检测方法,具有灵敏度高,特异性强,试剂配制简单的特点,值得进一步推广使用。
背景技术:
C3是血清中含量最高的补体成分,由巨噬细胞、单核细胞、淋巴组织、骨髓、腹膜和肝脏等合成的一种β球蛋白,在C3转化酶的作用下,裂解成C3a和C3b两个片段,在补体经典激活途径和旁路激活途径中均发挥重要作用。
C3是补体各成分中含量最高的一种,且是补体激活途径中最重要的环节,故其含量的测定非常重要。C3增多与减少与总补体活性基本相符,但更为敏感。约70%-80%的急性肾小球肾炎、狼疮性肾炎患者血清C3含量减少,病情缓解后可恢复正常,故C3的测定不仅有助于诊断,还可以观察疗效和监测预后。C3降低还可见于自身免疫性疾病、新生儿呼吸窘迫综合征、菌血症、组织损害和慢性肝炎。
补体C3的检测方法有单向免疫扩散法、ELISA法、免疫透射比浊法等。单向免疫扩散法费时,变异大,结果不易观察,测量直径不精确;ELISA法重复性不好,易出现假阳性,受温度和时间影响最大;免疫透射比浊法相对优于之前两种方法,但存在所需抗血清量大的缺点。本发明采用胶乳增强免疫比浊法,不仅灵敏度高,准确性好,不费时的优点,而且所需的样本量极少,更加经济节约。
发明内容:
本发明的目的在于,大量制备补体C3胶乳试剂,以提高补体C3检测效率,增强检测准确性。
本发明的技术方案:应用化学方法交联,通过水溶性碳化二亚胺(EDC)与N-羟基琥珀酰亚胺(NHS)使羊抗人补体C3抗血清与羧化聚苯乙烯胶乳共价交联,形成补体C3胶乳试剂。具体操作如下:
补体C3胶乳试剂的制备:
取粒径为100nm浓度为5%胶乳微球1ml,加入100mmol/L,PH6.0的磷酸盐缓冲液9ml,混合均匀后分别加入5mg水溶性碳化二亚胺(EDC)与N-羟基琥珀酰亚胺(NHS),室温搅拌20min,2-8℃离心30min(转速12000),用100mmol/L,PH6.0的磷酸盐缓冲液洗涤三次,除去上清液,取沉淀用100mmol/L,PH6.0的磷酸盐缓冲液1ml重悬,并加入200μl羊抗人补体C3抗血清,室温搅拌5h,2-8℃离心30min(转速12000),沉淀用含0.05%吐温-20(Tween 20),100mmol/L,PH6.0的磷酸盐缓冲液洗涤三次,除去上清液,所得沉淀用100mmol/L,PH6.0的磷酸盐缓冲液进行稀释,2-8℃密封保存。
本检测方法的原理为将羊抗人补体C3抗体交联于胶乳微粒上,与待测样品中的补体C3发生抗原-抗体反应,引起微粒凝集,形成一定的浊度,在340nm波长下,通过同样处理的校准品对照,定量检测出样品中补体C3的含量。
附图说明:
图1分别采用本发明试剂与市售试剂A,采用奥林巴斯400全自动生化分析仪,对50份样本(包含正常和异常样本),按各自参数进行测定,并对测定值进行相关分析。其中X轴表示的是本发明试剂的测定值,Y轴表示的是市售试剂A的测定值。相关系数:r2=0.9948,线性方程为:y=1.041x-0.054。
图2:采用奥林巴斯400全自动生化分析仪,对5个梯度浓度的试剂进行测定,并对测定值进行相关分析。其中X轴表示的是稀释浓度,Y轴表示的是测定值均值。相关系数:r2=0.9963,线性方程为:y=1.0272x-0.0007。
具体实施方式:
实施例
将本发明方法配制成试剂盒,进行与市售试剂盒进行性能比较:
本发明试剂配成试剂盒的具体成分如下:
补体C3检测试剂的使用:
1)检测仪器:具有340nm波长、37℃恒温装置的生化分析仪。
2)待测样本:新鲜不溶血血清,2-8℃可稳定七天。-20℃可稳定一个月。
3)具体检测程序:
4)计算结果:补体C3浓度(g/L)=ΔAT/ΔAS×Cs
ΔAT:样品管吸光度
ΔAS:校准管吸光度
Cs:校准品浓度值
5)参考值范围:0.9~1.5g/L
6)精密度:批内CV≤4%;批间相对极差≤6%。
7)准确度:相对偏差控制在±10%内。
8)线性范围:在0.1~3g/L范围内,相关系数r≥0.990。
对照的市售进口试剂A,其信息如下:
产品名称:补体C3检测试剂盒(免疫比浊法)
检测原理:人血清中补体C3与抗血清试剂中的C3抗体形成抗原抗体复合物,使反应液出现浊度,在340nm下检测吸光度的变化与标准品比较测得血清中补体C3的浓度。
主要组成成份:
试剂R1:TRIS缓冲液:100mmol/L,pH 8.0
聚乙二醇:3.0%
防腐剂
试剂R2:抗人C3/C3b/C3c抗体(山羊):根据滴度
TRIS缓冲液:33mmol/L
防腐剂
市售试剂A按说明书操作。
实例1本发明试剂与市售试剂A的性能指标比较:
1)精密度测定:同一样品中连续抽取20次进行测定,计算测定值的均数、标准差和变异系数,
表1精密度检测结果
变异系数CV通常用于衡量一项测定方法的精密度,CV值越小,表示该测定方法的结果精密度越好。对于临床化学检验项目而言,CV小于5%的方法精密度公认是可以接受的。表1中本发明试剂的CV值小于市售试剂A,表明本发明方法的精密度略优于市售试剂A。
2)线性测定:分别采用本发明试剂与市售试剂A,采用奥林巴斯400全自动生化分析仪,对50份样本(包含正常和异常样本),按各自参数进行测定,并对测定值进行相关分析(结果见图1,X轴表示的是本发明试的测定值,Y轴表示的是市售试剂A的测定值)。相关系数:r2=0.9948,线性方程为:y=1.041x-0.054,结果表明本试剂与市售试剂相关性良好。
表2线性相关检测结果
实例2本发明试剂配制成试剂盒相关性能评估
1)精密度测定:同一样品中连续抽取20次进行测定,计算测定值的均数、标准差和变异系数,
表3精密度检测结果
变异系数CV通常用于衡量一项测定方法的精密度,CV值越小,表示该测定方法的结果精密度越好。对于临床化学检验项目而言,CV小于5%的方法精密度公认是可以接受的。表3中CV值小于3%,表明本发明方法具有优良的精密度。
2)准确度测定:用同一质控品,重复测定3次,取平均值,与质控品靶值相对偏差应在±10%范围内。
表4准确度检测结果
表4中相对偏差CB=-2.00%,处于±10%范围内,表明本发明方法具有优良的准确度。
3)线性测定:使用去离子水将试剂稀释成5个梯度浓度,每个梯度浓度检测3次,取平均值,对测定值与预期值作回归分析,计算r值和相对偏差(结果见图2,单位g/L)。
表5线性相关检测结果
通过表5得到相关系数:r2=0.9963,线性方程为:y=1.0272x-0.0007,结果表明本试剂相关性良好。
4)稳定性测定:将本发明检测试剂分别放置在室温和4℃冰箱,以新鲜配制的3.0g/L人补体C3标准品替代样品,每隔1个月测定1次,记录出现凝集所需时间,结果见表6。结果表明,试剂盒在4℃冰箱放置至少6个月以上不会有明显活性丧失,但不宜在室温存放。
表6稳定性检测结果
室温下 | 出现凝集的时间(min) | 4℃下 | 出现凝集的时间(min) |
新配制 | 1 | 新配制 | 1 |
存放1个月 | 2 | 存放1个月 | 1 |
存放2个月 | 不凝集 | 存放2个月 | 1 |
存放3个月 | 不凝集 | 存放3个月 | 1 |
存放4个月 | 不凝集 | 存放4个月 | 1 |
存放5个月 | 不凝集 | 存放5个月 | 1 |
存放6个月 | 不凝集 | 存放6个月 | 1 |
5)特异性测定:选取3种潜在干扰物进行干扰实验测定,均无抑制效果,表明该试剂盒有良好特异性,结果如表7所示:
表7特异性检测结果
Claims (4)
1.本发明提供一种补体C3检测方法,所述检测方法基于胶乳增强免疫比浊法,为液体双试剂,包括试剂R1与R2,所述试剂R1含PH6.0磷酸盐缓冲液,吐温-20(Tween 20),乙二胺四乙酸二钠(EDTA-2Na),氯化钠,聚乙二醇(PEG6000),叠氮钠;试剂R2为含有补体C3胶乳颗粒的溶液,其特点在于应用化学方法交联,通过水溶性碳化二亚胺(EDC)与N-羟基琥珀酰亚胺(NHS)使羊抗人补体C3抗血清与羧化聚苯乙烯胶乳共价交联,形成补体C3胶乳试剂。
2.根据权利要求1所述化学交联方法制备补体C3胶乳试剂,其特征在于所用的羧化聚苯乙烯胶乳粒径为100nm。
3.根据权利要求1所述化学交联方法制备补体C3胶乳试剂,其特征在于羧化聚苯乙烯胶乳与羊抗人C3抗血清共价交联过程中分别添加水溶性碳化二亚胺(EDC)与N-羟基琥珀酰亚胺(NHS)。
4.根据权利要求1所述,其特征在于样品中mAlb的计算公式为:
样品中补体C3浓度(g/L)=Cs×ΔAT/ΔAS
式中:ΔAT以空白管吸光度为对照的样品管吸光度;
ΔAS以空白管吸光度为对照的校准管吸光度;
CS校准液中补体C3的浓度。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510226757.7A CN104833810A (zh) | 2015-05-02 | 2015-05-02 | 一种补体c3检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510226757.7A CN104833810A (zh) | 2015-05-02 | 2015-05-02 | 一种补体c3检测方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104833810A true CN104833810A (zh) | 2015-08-12 |
Family
ID=53811822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510226757.7A Pending CN104833810A (zh) | 2015-05-02 | 2015-05-02 | 一种补体c3检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104833810A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106483299A (zh) * | 2016-10-03 | 2017-03-08 | 王贤俊 | 一种用于检测人血清中超氧化物歧化酶含量的方法 |
CN107490676A (zh) * | 2017-08-10 | 2017-12-19 | 迈克生物股份有限公司 | 一种补体c3检测试剂盒及检测方法 |
CN109752332A (zh) * | 2017-11-07 | 2019-05-14 | 重庆中元汇吉生物技术有限公司 | 一种补体C1q检测试剂盒 |
CN111693697A (zh) * | 2020-07-07 | 2020-09-22 | 上海怡珏生物科技有限公司 | C3c抗体在制备检测试剂盒中的用途 |
-
2015
- 2015-05-02 CN CN201510226757.7A patent/CN104833810A/zh active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106483299A (zh) * | 2016-10-03 | 2017-03-08 | 王贤俊 | 一种用于检测人血清中超氧化物歧化酶含量的方法 |
CN107490676A (zh) * | 2017-08-10 | 2017-12-19 | 迈克生物股份有限公司 | 一种补体c3检测试剂盒及检测方法 |
CN109752332A (zh) * | 2017-11-07 | 2019-05-14 | 重庆中元汇吉生物技术有限公司 | 一种补体C1q检测试剂盒 |
CN111693697A (zh) * | 2020-07-07 | 2020-09-22 | 上海怡珏生物科技有限公司 | C3c抗体在制备检测试剂盒中的用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101769932B (zh) | 全量程c反应蛋白检测试剂盒 | |
Evans | Manual and automated methods for measuring urea based on a modification of its reaction with diacetyl monoxime and thiosemicarbazide. | |
CN110862881B (zh) | 一种全自动化学发光测定仪专用的清洗液或其稀释液及其制备方法 | |
CN102253217B (zh) | 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 | |
CN102621332B (zh) | 基于胶乳粒子包被视黄醇结合蛋白检测试剂盒 | |
CN102507918B (zh) | 抗环瓜氨酸肽抗体测定试剂盒 | |
CN101699287B (zh) | 匀相溶胶颗粒型胱抑素c测定试剂盒及其制备方法 | |
CN103592445A (zh) | 检测降钙素原的试剂盒 | |
CN105510604A (zh) | 一种提高胶乳试剂灵敏度和线性的方法 | |
CN102393456B (zh) | 一种用于检测hps的试剂盒 | |
JP6749337B2 (ja) | 前立腺抗原標準およびその使用 | |
CN104849473A (zh) | 一种尿微量白蛋白检测试剂盒及其制备 | |
CN104215770A (zh) | 一种基于双粒子的视黄醇结合蛋白检测试剂盒 | |
CN104034893B (zh) | 一种基于胶乳的三聚氰胺快速检测方法及试剂盒 | |
CN104833810A (zh) | 一种补体c3检测方法 | |
CN105203748A (zh) | 一种全量程c反应蛋白的定量检测试剂盒 | |
CN105277717A (zh) | 一种甲状腺球蛋白的磁微粒分离化学发光免疫检测方法 | |
CN102243241A (zh) | 一种匀相溶胶颗粒型中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒及其制备方法 | |
CN107247138B (zh) | 一种用于测定d-二聚体含量的化学发光板的包被方法 | |
CN105699665A (zh) | 一种中性粒细胞明胶酶相关脂质运载蛋白的检测试剂盒 | |
CN108663526B (zh) | 二抗竞争免疫比浊测定试剂盒及其制作和使用方法 | |
CN104849224A (zh) | 一种补体c3检测试剂盒及其制备 | |
CN109521200A (zh) | 一种同时检测血浆中多种成分含量的试剂盒、方法及其应用 | |
CN103529221A (zh) | 一种用于检测血清中酸性糖蛋白含量的试剂盒 | |
CN105259344A (zh) | 一种使用磁微粒化学发光定量检测抗Scl-70抗体IgG的试剂盒及其制备方法和检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150812 |